Projektbeschreibung
Neurodegeneration an den Synapsen erneut auf der Tagesordnung
Neurodegenerative Erkrankungen wie Alzheimer und Parkinson sind durch die Fehlfaltung und Anhäufung bestimmter Proteine gekennzeichnet. Während sich ein Großteil der Forschung auf die Degeneration von Neuronen konzentriert haben, gibt es immer mehr Hinweise darauf, dass diese Krankheiten tatsächlich an den Synapsen beginnen können. Aufgabe des im Rahmen der Marie-Skłodowska-Curie-Maßnahme finanzierten Projekts SYNDEGEN wird sein, Fachleute auf diesem Gebiet zusammenzubringen, um die physiologische Rolle dieser Proteine und ihre Beteiligung an synaptischen Dysfunktionen zu untersuchen. Der Schwerpunkt des Konsortiums liegt auf der umfassenden Ausbildung der nächsten Wissenschaftsgeneration auf diesem Gebiet, um so neue Erkenntnisse und die Entwicklung neuer therapeutischer Ansätze zu fördern.
Ziel
Neurodegenerative diseases (NDDs) of aging are a growing burden on societies. Although studies on the degeneration of neurons have been a main focus of research, increasing evidence points to synapses as the site where Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD) begin. There is growing evidence that synapses are sites of early and aberrant protein misfolding, aggregation and spread in NDDs. A key problem in research on NDDs has been that the normal physiological roles at synapses of the aggregation-prone proteins (β- amyloid/amyloid precursor protein, tau, α-synuclein and huntingtin), which are linked pathologically and genetically to these diseases, are not known. Using cutting-edge technologies and multidisciplinary approaches the SYNDEGEN consortium aims to bring together leading experts in cell biology, synapse biology and imaging, stem cell biology and NDDs in Europe to determine the molecular and cellular mechanisms whereby synapses become dysfunctional in AD, PD and HD for the purpose of developing novel therapies. The goal of the consortium is to train talented young scientists in interdisciplinary, innovative and collaborative research aimed at the development of novel molecular based treatment strategies for these major diseases of aging. A gap in the training of students in these important diseases is that disease expertise and novel methods to study synapses are localized in isolated groups in different locations in the EU. Similar questions are being asked about the mechanisms of synaptic dysfunction in AD, PD and HD, but no one university or company has sufficiently broad knowledge and technical expertise required to study and develop therapies for synaptic dysfunction in these disorders. This training programme will be implemented in 6 academic centres and 2 SMEs representing a comprehensive, highly interactive and multidisciplinary partnership.
Wissenschaftliches Gebiet
- medical and health sciencesbasic medicineneurologydementiaalzheimer
- medical and health sciencesbasic medicinephysiologypathophysiology
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsprotein folding
- medical and health sciencesbasic medicineneurologyparkinson
Programm/Programme
Thema/Themen
Aufforderung zur Vorschlagseinreichung
Andere Projekte für diesen Aufruf anzeigenFinanzierungsplan
MSCA-ITN-ETN - European Training NetworksKoordinator
22100 Lund
Schweden